232 related articles for article (PubMed ID: 28302995)
1. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
[TBL] [Abstract][Full Text] [Related]
2. Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience.
Jiménez-Romero C; Manrique A; Marqués E; Calvo J; Sesma AG; Cambra F; Abradelo M; Sterup RM; Olivares S; Justo I; Colina F; Moreno E
Hepatogastroenterology; 2011; 58(105):115-21. PubMed ID: 21510297
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
4. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
5. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation.
Montano-Loza AJ; Vargas-Vorackova F; Ma M; Bain VG; Burak K; Kumar T; Mason AL
Liver Int; 2012 Oct; 32(9):1426-33. PubMed ID: 22712495
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C
Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I
Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656
[TBL] [Abstract][Full Text] [Related]
9. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation.
Jiménez-Pérez M; González Grande R; Rando Muñoz FJ; de la Cruz Lombardo J; Muñoz Suárez MA; Fernández Aguilar JL; Pérez Daga JA; Santoyo-Santoyo J; Manteca González R; Rodrigo López JM
Transplant Proc; 2015; 47(1):90-2. PubMed ID: 25645779
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
[TBL] [Abstract][Full Text] [Related]
12. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
[TBL] [Abstract][Full Text] [Related]
13. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil in liver transplantation: a review.
Kaltenborn A; Schrem H
Ann Transplant; 2013 Dec; 18():685-96. PubMed ID: 24346057
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients.
Colmenero J; Rodríguez-Perálvarez M; Salcedo M; Arias-Milla A; Muñoz-Serrano A; Graus J; Nuño J; Gastaca M; Bustamante-Schneider J; Cachero A; Lladó L; Caballero A; Fernández-Yunquera A; Loinaz C; Fernández I; Fondevila C; Navasa M; Iñarrairaegui M; Castells L; Pascual S; Ramírez P; Vinaixa C; González-Dieguez ML; González-Grande R; Hierro L; Nogueras F; Otero A; Álamo JM; Blanco-Fernández G; Fábrega E; García-Pajares F; Montero JL; Tomé S; De la Rosa G; Pons JA
J Hepatol; 2021 Jan; 74(1):148-155. PubMed ID: 32750442
[TBL] [Abstract][Full Text] [Related]
16. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.
Crane GM; Powell H; Kostadinov R; Rocafort PT; Rifkin DE; Burger PC; Ambinder RF; Swinnen LJ; Borowitz MJ; Duffield AS
Oncotarget; 2015 Oct; 6(32):33849-66. PubMed ID: 26460822
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial.
Schmeding M; Kiessling A; Neuhaus R; Heidenhain C; Bahra M; Neuhaus P; Neumann UP
Transplantation; 2011 Oct; 92(8):923-9. PubMed ID: 21832958
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
Manrique A; Jiménez C; Ortega P; Abradelo M; Gimeno A; Calvo J; Cambra F; -Sterup RL; Morales JM; Moreno E
Transplant Proc; 2008 Nov; 40(9):2962-4. PubMed ID: 19010160
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil monotherapy in stable liver transplant recipients with progressive renal failure.
Detry O; De Roover A; Honoré P; Delwaide J; Jacquet N; Meurisse M
Transplant Proc; 2002 May; 34(3):782-3. PubMed ID: 12034182
[No Abstract] [Full Text] [Related]
20. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
